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CI

:   confidence interval

CRC

:   colorectal cancer

FIT

:   fecal immunochemical test

GI

:   gastrointestinal

HCC

:   hepatocellular carcinoma

HE

:   hepatic encephalopathy

IBD

:   inflammatory bowel disease

INR

:   international normalized ratio

IQR

:   interquartile range

MELD

:   model for end‐stage liver disease

OR

:   odds ratio

PSC

:   primary sclerosing cholangitis

SBP

:   spontaneous bacterial peritonitis

SD

:   standard deviation

SSA/P

:   sessile serrated adenoma/polyp

TSA

:   traditional serrated adenoma

Colonoscopy is commonly performed as part of the standard screening for neoplastic lesions in patients who are candidates for liver transplantation, although international guidelines do not clearly state in which patients it should be mandatorily performed or might be omitted.[1](#hep30562-bib-0001){ref-type="ref"}, [2](#hep30562-bib-0002){ref-type="ref"}, [3](#hep30562-bib-0003){ref-type="ref"}

The prevalence of colorectal cancer (CRC) in liver transplantation candidates has not been well defined. Several studies have reported that the prevalence of premalignant colon lesions (i.e., advanced adenomas) in this patient population varies from 5.8% to 13.9%.[4](#hep30562-bib-0004){ref-type="ref"}, [5](#hep30562-bib-0005){ref-type="ref"}, [6](#hep30562-bib-0006){ref-type="ref"}, [7](#hep30562-bib-0007){ref-type="ref"}, [8](#hep30562-bib-0008){ref-type="ref"} Removal of these precursor lesions is recommended, considering the potentially accelerated rate of progression to CRC during long‐term immunosuppressive therapy after transplantation.[9](#hep30562-bib-0009){ref-type="ref"}

In addition, few quantitative data are available pertaining to the safety of colonoscopy in this population. Several case series have suggested that patients with end‐stage liver disease undergoing colonoscopy are at increased risk for hemorrhage and perforation after polypectomy.[10](#hep30562-bib-0010){ref-type="ref"}, [11](#hep30562-bib-0011){ref-type="ref"} Other reported complications include bacteremia, peritonitis, and renal failure.[12](#hep30562-bib-0012){ref-type="ref"}, [13](#hep30562-bib-0013){ref-type="ref"}, [14](#hep30562-bib-0014){ref-type="ref"}, [15](#hep30562-bib-0015){ref-type="ref"}, [16](#hep30562-bib-0016){ref-type="ref"}, [17](#hep30562-bib-0017){ref-type="ref"}, [18](#hep30562-bib-0018){ref-type="ref"}, [19](#hep30562-bib-0019){ref-type="ref"}

The aim of the present study was to assess the yield and safety of screening colonoscopy in a large consecutive cohort of patients who underwent evaluation for liver transplantation by investigating the prevalence and predictive factors for CRC and advanced adenomas and the incidence and predisposing factors for postprocedural complications.

Patients and Methods {#hep30562-sec-0002}
====================

Study Design and Patients {#hep30562-sec-0003}
-------------------------

All consecutive patients undergoing colonoscopy during pre--liver transplantation screening from January 1, 2004, to May 1, 2017, in the Erasmus Medical Center, Rotterdam, the Netherlands, were retrospectively included. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in approval by the institution\'s human research committee on January 23, 2017. Written informed consent was not necessary, considering the nature of the study.

Colonoscopy Procedure {#hep30562-sec-0004}
---------------------

Bowel preparation was achieved using polyethylene electrolyte glycol (PEG) solutions. Sedation, using midazolam and/or fentanyl, was performed at the discretion of the patients' preference and physicians' judgement. Endoscopic reports were retrieved from the automated EndoALPHA reporting system (ENDOBASE; Olympus Winter & Ibe, Hamburg, Germany). Specimens of resected colon tissue were processed and reviewed by specialized gastrointestinal (GI) pathologists using standard histologic methods.

Data Collection {#hep30562-sec-0005}
---------------

Clinical patient characteristics at the time of colonoscopy, including sex, age, cause and severity of liver disease, presence of hepatocellular carcinoma (HCC), presentence of ascites (graded as none, diuretic‐responsive, and refractory), presence of hepatic encephalopathy (HE) (graded according to the West‐Haven criteria), and laboratory values (creatinine, albumin, bilirubin, and international normalized ratio \[INR\]), were collected from electronic patient records. Data of the colonoscopy procedure, including use of premedication, adequacy of bowel preparation, cecal intubation rate, tumor size, morphologic and histopathologic characteristics, polyps, and other endoscopic findings (e.g., inflammatory bowel disease \[IBD\], rectal varices, and portal enteropathy), were recorded. In the context of this study, patients were followed until 1 year after liver transplantation, until the date of death when not undergoing transplant, or until the end of the study observation period (August 1, 2018) when they were still on the waiting list.

Complications {#hep30562-sec-0006}
-------------

All clinical events potentially related to the colonoscopy were registered in the 30‐day period after the procedure. To assess colonoscopy‐associated risk in comparison with the general risk in this particular population, relevant clinical events were also registered in the 30‐day period preceding the procedure when this was performed in even years (e.g., 2004, 2006, and so on) and between day 31 and day 60 after the procedure when this was performed in uneven years (Fig. [1](#hep30562-fig-0001){ref-type="fig"}). Patients who received a liver transplantation or who died during the control time frame were not taken into account with respect to the assessment of complications. The following events were considered to be potentially related to colonoscopy: postpolypectomy hemorrhage, colon perforation, acute renal failure, GI bleeding, new onset or worsening of ascites and HE, bacterial infections (including bacteremia, fever of unknown origin, spontaneous bacterial peritonitis \[SBP\], and respiratory, urogenital, and other infections), cardiopulmonary events (including new‐onset arrhythmias, myocardial infarction, congestive heart failure, aspiration pneumonia, and respiratory insufficiency), and significant rise in serum bilirubin.

![Schematic view of the chosen control time frames in this study.](HEP-69-2598-g001){#hep30562-fig-0001}

Definitions {#hep30562-sec-0007}
-----------

Liver disease severity scores were calculated, and patients were classified according to Child‐Pugh class.[20](#hep30562-bib-0020){ref-type="ref"} The model for end‐stage liver disease (MELD) score was calculated with the following formula: 0.957 × log(creatinine in milligrams per deciliter) + 0.378 × log(bilirubin in milligrams per deciliter) + 1.120 × log(INR) + 0.643.[21](#hep30562-bib-0021){ref-type="ref"}, [22](#hep30562-bib-0022){ref-type="ref"} The adequacy of bowel preparation was classified as inadequate, poor, fair, good, or excellent using the Aronchick bowel preparation scale.[23](#hep30562-bib-0023){ref-type="ref"}, [24](#hep30562-bib-0024){ref-type="ref"} Cecal intubation was defined as complete visualization and intubation of the cecum, confirmed by the visual landmarks of the ileocecal valve and triradiate cecal fold.[25](#hep30562-bib-0025){ref-type="ref"} Patients with an inadequate or poor bowel preparation were excluded from cecal intubation rate calculations. Colon tissue specimens were classified as normal colon tissue, hyperplastic polyps, inflammatory polyps, nonadvanced adenomas, advanced adenomas, or CRC.[26](#hep30562-bib-0026){ref-type="ref"} Nonadvanced adenoma was defined as all tubular adenoma and serrated nonadvanced adenoma.[26](#hep30562-bib-0026){ref-type="ref"} Sessile serrated adenoma/polyp (SSA/P) was defined as predominantly architectural distortion with irregular dilated crypts that often have an *L* or *T* shape.[27](#hep30562-bib-0027){ref-type="ref"} Traditional serrated adenoma (TSA) was defined as protuberant or pedunculated grown pattern with distorted villiform configurations, with columnar cells having abundant eosinophilic cytoplasm or centrally located elongated nuclei.[27](#hep30562-bib-0027){ref-type="ref"} Advanced adenomas were defined as adenomas ≥10 mm, adenomas with high‐grade dysplasia, or adenomas with a villous component of at least 25%.[26](#hep30562-bib-0026){ref-type="ref"}, [28](#hep30562-bib-0028){ref-type="ref"} Cancers were staged according to the TNM staging system, described in the seventh edition of the American Joint Committee on Cancer staging manual.[29](#hep30562-bib-0029){ref-type="ref"} Advanced neoplasia was defined as advanced adenoma and/or CRC.

Acute renal failure was defined as a serum creatinine increase by 50% or more within 7 days or an increase of 0.3 mg/dL (26.5 μmol/L) within 2 days.[30](#hep30562-bib-0030){ref-type="ref"}, [31](#hep30562-bib-0031){ref-type="ref"} GI bleeding was defined as all forms of variceal bleeding in the upper or lower GI tract (thus excluding bleeding form a polypectomy site).[32](#hep30562-bib-0032){ref-type="ref"} New‐onset or worsening HE was defined as newly diagnosed HE or an increase of neurocognitive changes according to the West‐Haven clinical criteria.[33](#hep30562-bib-0033){ref-type="ref"}, [34](#hep30562-bib-0034){ref-type="ref"} New‐onset ascites or worsening ascites were defined as a sudden increase of ascites and confirmation by ultrasound or fluid drainage by paracentesis. Bacterial infections were classified using Centers for Disease Control and Prevention criteria.[35](#hep30562-bib-0035){ref-type="ref"}, [36](#hep30562-bib-0036){ref-type="ref"} Fever of unknown origin was defined as a prolonged febrile illness that persists without diagnosis after careful initial assessment.[37](#hep30562-bib-0037){ref-type="ref"} SBP was defined as a polymorphonuclear cell count in ascites ≥250/μL without a surgically treatable abdominal source of infection.[38](#hep30562-bib-0038){ref-type="ref"} A bilirubin increase was defined as an increase of at least 5 mg/dL (85 μmol/L) within 2 days.

Statistical Analysis {#hep30562-sec-0008}
--------------------

Continuous variables were reported as the mean with standard deviation (SD) after visual confirmation of approximate normality and were compared using the Student *t* test. Continuous variables with a nonnormal distribution were reported as the median with interquartile range (IQR) expressed as the twenty‐fifth to the seventy‐fifth percentile. Categorical variables were reported as count with proportion and compared using the chi‐square test. A two‐sided *P* value \< 0.05 was considered significant.

Multivariable logistic regression, carried out to identify risk factors for cecal intubation failure, included the following candidate predictor variables: sex, age, MELD score, ascites, HE, and sedation medication during colonoscopy. Multivariable logistic regression, carried out to identify risk factors for an advanced neoplasm, included the following candidate predictor variables: sex, age, liver disease cause, HCC, MELD score, and CRC screening (i.e., colonoscopy, fecal occult blood test \[FOBT\]/fecal immunochemical test \[FIT\], computed tomography \[CT\] colonography, or barium enema examination) in the prior 5 years. Multivariable analyses for the logistic regression models were employed using the backward stepwise selection method with removal testing based on the significance of the likelihood‐ratio statistic.

Kaplan‐Meier analysis was used to estimate 1‐year and 2‐year survival rates after liver transplantation.

All statistical analyses were performed using IBM SPSS Statistics for Windows, version 24.0.0.1 (IBM Corp., Armonk, NY).

Results {#hep30562-sec-0009}
=======

Patient Characteristics {#hep30562-sec-0010}
-----------------------

From January 1, 2004, to May 1, 2017, 1,145 patients underwent pre--liver transplantation screening in the Erasmus MC, Rotterdam, the Netherlands. A total of 337 patients were not included in the study, mainly because colonoscopy was performed in a referring hospital (n = 90), patients were listed with highly urgent priority (n = 74), or the screening was prematurely terminated because of clinical deterioration of the patient condition (n = 41). The remaining 808 patients were included for the present analysis (Fig. [2](#hep30562-fig-0002){ref-type="fig"}). The study cohort included 524 men and 284 women with a median age 55 years (IQR, 47‐62) at the time of colonoscopy (Table [1](#hep30562-tbl-0001){ref-type="table"}). The most frequent reason for pre--liver transplantation screening was alcoholic liver disease (22.9%), followed by viral hepatitis (21.4%) and primary sclerosing cholangitis (PSC) (17.6%) (Table [1](#hep30562-tbl-0001){ref-type="table"}). The prevalence of IBD in patients diagnosed with PSC was 59.9% (85/142 patients). HCC was present in 223 patients (27.6%). The median MELD score was 15 (IQR, 11‐18; range, 6‐40), 24.5% of patients had diuretic‐responsive ascites, 16.6% had refractory ascites, and 97 (12%) patients had HE at the time of colonoscopy. Approximately 20% of patients used at least one antibiotic agent during colonoscopy. One‐fifth of patients received colorectal screening in the prior 5 years by colonoscopy; no cases were identified of patients undergoing colonoscopy after a positive screening with FOBT/FIT, CT colonography, or barium enema examination (Table [1](#hep30562-tbl-0001){ref-type="table"}).

![Flow chart of study inclusion.](HEP-69-2598-g002){#hep30562-fig-0002}

###### 

Patient Baseline Clinical Characteristics at the Time of Screening Colonoscopy

                                                                  Patients (n = 808)
  --------------------------------------------------------------- --------------------
  Male sex, n (%)                                                 524 (64.9)
  Age in years, median (IQR)                                      55 (47‐62)
  Cause of liver disease, n (%)                                   
  Alcoholic liver disease                                         185 (22.9)
  Viral hepatitis                                                 173 (21.4)
  PSC                                                             142 (17.6)
  PBC/autoimmune hepatitis                                        65 (8.0)
  Cryptogenic liver cirrhosis                                     58 (7.2)
  NASH                                                            41 (5.1)
  Other                                                           144 (17.8)
  HCC, n (%)                                                      223 (27.6)
  Blood serum parameters                                          
  Creatinin (μmol/L), median (IQR)                                71 (59‐90)
  Albumin (g/L), mean (SD)                                        33 (±7)
  Bilirubin (μmol/L), mean (SD)                                   87 (±126)
  INR, mean (SD)                                                  1.4 (±0.4)
  Liver disease severity scores                                   
  MELD score, median (IQR)                                        15 (11‐18)
  Child‐Pugh class, n (%)                                         
  A                                                               473 (58.5)
  B                                                               294 (36.4)
  C                                                               41 (5.1)
  Ascites, n (%)                                                  
  None                                                            476 (58.9)
  Diuretic‐responsive                                             198 (24.5)
  Refractory                                                      134 (16.6)
  HE, n (%)                                                       
  None                                                            711 (88.0)
  West‐Haven grade 1‐2                                            71 (8.8)
  West‐Haven grade 3‐4                                            26 (3.2)
  Antibiotic use,[\*](#hep30562-note-0004){ref-type="fn"} n (%)   162 (20.0)
  Norfloxacin                                                     82 (10.1)
  Rifaximin                                                       48 (5.9)
  Rifamipicin                                                     9 (1.1)
  Ciprofloxacin                                                   17 (2.1)
  Amoxicilin and clavulanic acid                                  5 (0.6)
  Other                                                           12 (1.5)
  Colorectal screening in the prior 5 years, n (%)                193 (23.9)

11 patients used multiple antibiotic agents.

Abbreviations: NASH, nonalcoholic steatohepatitis; PBC, primary biliary cirrhosis.

John Wiley & Sons, Ltd

Colonoscopy Procedure {#hep30562-sec-0011}
---------------------

A total of 864 colonoscopies were performed in 808 patients. Bowel preparation adequacy was available in 663 patients and was scored as excellent in 7.1%, good in 54.6%, fair in 16.1%, poor in 3.3%, and inadequate in 1%. Cecal intubation rate of the index colonoscopy was 96.7%. Cecal intubation failed because of loop formation in 15 patients and because of abortion due to patient discomfort/abdominal pain in 12 patients. Multivariable logistic regression, carried out for risk factors for cecal intubation failure, identified MELD score (odds ratio \[OR\], 1.090 per point; 95% confidence interval \[CI\], 1.015‐1.170; *P* = 0.018) as an independent risk factor.

In total, 56 repeat colonoscopies were performed because of several reasons: poor bowel preparation (n = 13), initial cecal intubation failure (n = 25), anticoagulation status contraindicated polypectomy (n = 9), patients needed a repeat colonoscopy after a period of 3 years on the liver transplantation waiting list or for liver retransplantation (n = 6), or additional polypectomy or surveillance after polypectomy (n = 3). In 6 patients with initial cecal intubation failure and in 5 patients with poor bowel preparation, subsequent colonoscopy was postponed until after the transplantation.

In this cohort, 799/864 (92.4%) colonoscopies were performed under conscious sedation using intravenous midazolam and fentanyl. Sixty‐five procedures were performed using fentanyl (n = 25), remifentanil (n = 7), or without any premedication (n = 33). Patients did not receive standard periprocedural antibiotic prophylaxis.

Diagnostic Yield {#hep30562-sec-0012}
----------------

In total, 625 polypectomies were performed during colonoscopy, with an average of 2.3 polypectomies (±1.3) per patient. At colonoscopy, advanced neoplasia was found in 46 (5.6%) patients: advanced adenoma in 44 (5.4%) and CRC in 2 (0.2%). Nonadvanced adenoma was found in 151 patients (18.7%), including SSA/P or TSA in 13 patients (1.6%), hyperplastic polyps in 130 patients (16.1%), and inflammatory polyps in 3 patients (0.4%) (Table [2](#hep30562-tbl-0002){ref-type="table"}).

###### 

Findings at Colonoscopy

                                                                          Patients (n = 808)
  ----------------------------------------------------------------------- --------------------
  Diagnostic yield,[\*](#hep30562-note-0006){ref-type="fn"} n (%)         
  CRC                                                                     2 (0.2)
  Advanced adenoma                                                        44 (5.4)
  ≥10 mm                                                                  17
  ≥25% villous                                                            9
  high‐grade dysplasia                                                    4
  ≥10 mm + high‐grade dysplasia                                           3
  ≥10 mm + ≥25% villous                                                   8
  ≥25% villous + high‐grade dysplasia                                     1
  ≥10 mm + ≥25% villous + high‐grade dysplasia                            2
  Nonadvanced adenoma                                                     164 (20.3)
  SSA/P or TSA                                                            13
  Hyperplastic polyp                                                      130 (16.1)
  Inflammatory polyp                                                      3 (0.4)
  No lesions                                                              465 (57.6)
  Other colon pathologies,[†](#hep30562-note-0007){ref-type="fn"} n (%)   
  IBD                                                                     92 (11.4)
  Rectal varices                                                          72 (8.9)
  Angiodysplasia                                                          61 (7.5)
  Portal hypertension                                                     58 (7.2)
  Diverticulosis                                                          57 (7.1)
  Hemorrhoids                                                             42 (5.2)

According to the most advanced lesion.

Patients could have multiple other pathologies.

John Wiley & Sons, Ltd

In 58 of the remaining 465 patients, a lesion was macroscopically present, but polypectomy was not attempted because of impaired coagulation and/or a macroscopically benign character (n = 41) or because histopathologic evaluation was not possible as a result of loss or insufficient yield of tissue (n = 17). At a subsequent colonoscopy, advanced adenoma was diagnosed in 3 of 58 cases, and CRC was diagnosed in none.

The only independent risk factor for advanced neoplasia was age (odds ratio, 1.072 per year; 95% CI, 1.031‐1.115; *P* \< 0.001). Advanced neoplasia was diagnosed in 5.6% of the patients aged 60 years or older, in 5.4% of the patients aged 50‐59 years, and in 1.8% of the patients aged 40‐49 years; no advanced neoplasm was diagnosed below the age of 40 years (Fig. [3](#hep30562-fig-0003){ref-type="fig"}). The 2 patients with CRC were a 62‐year‐old female with a T2N0M0 rectal adenocarcinoma and a 64‐year‐old female with a T2N0M0 adenocarcinoma of the sigmoid colon.

![Most advanced lesion per participant found during colonoscopy.](HEP-69-2598-g003){#hep30562-fig-0003}

Other Colon Pathologies {#hep30562-sec-0013}
-----------------------

In 294 patients (36.4%), other colon pathologies were reported (Table [2](#hep30562-tbl-0002){ref-type="table"}). There were no cases of newly diagnosed IBD.

Complications after Colonoscopy {#hep30562-sec-0014}
-------------------------------

During the 30‐day period after colonoscopy, 178 clinical events occurred in 128 (14.9%) patients compared with 101 clinical events in 72 (8.6%) patients in the control time frames (*P* \< 0.001) (Table [3](#hep30562-tbl-0003){ref-type="table"}).

###### 

Frequency of Complications in Patients Undergoing Screening Colonoscopy

                                            Complications During 30 Days After Colonoscopy (n = 858)   Complications During 30‐Day Control Time Frame (n = 835)   *P* Value
  ----------------------------------------- ---------------------------------------------------------- ---------------------------------------------------------- -----------
  Acute renal failure, n (%)                33 (3.8)                                                   10 (1.2)                                                   **0.001**
  Gastrointestinal bleed, n (%)             25 (2.9)                                                   11 (1.3)                                                   **0.023**
  Bacterial infection, n (%)                54 (6.3)                                                   37 (4.4)                                                   0.089
  SBP                                       18                                                         17                                                         ---
  Fever of unknown origin                   15                                                         6                                                          ---
  Bloodstream infection                     12                                                         3                                                          ---
  Respiratory infection                     4                                                          ‐                                                          ---
  GI infection                              4                                                          7                                                          ---
  Urogenital infection                      3                                                          3                                                          ---
  Other                                     0                                                          1                                                          ---
  HE, n (%)                                 47 (5.5)                                                   32 (3.8)                                                   0.109
  Pulmonary complications, n (%)            10 (1.2)                                                   3 (0.4)                                                    0.058
  (Aspiration) pneumonia                    3                                                          ---                                                        ---
  Respiratory insufficiency                 7                                                          3                                                          ---
  Cardiac complications, n (%)              7 (0.8)                                                    4 (0.5)                                                    0.391
  New‐onset arrhythmia                      5                                                          1                                                          ---
  Congestive heart failure                  2                                                          2                                                          ---
  Myocardial ischemia                       ---                                                        1                                                          ---
  Ascites (new‐onset or worsening), n (%)   1 (0.1)                                                    4 (0.5)                                                    0.169
  Bilirubin increase, n (%)                 1 (0.1)                                                    ---                                                        0.324

Bold indicates a *P* value below 0.05.

John Wiley & Sons, Ltd

After colonoscopy, there was a significantly increased risk for acute renal failure (33 vs. 10; *P* = 0.001). Patients with acute renal failure had an average creatinine rise of 66 μmol/L; 35 were treated with volume expansion, albumin, and/or vasopressors, and 8 were treated with dialysis. The presence of ascites (diuretic‐responsive ascites OR, 1.199; 95% CI, 0.356‐4.038; refractory ascites OR, 5.384; 95% CI, 1.935‐14.978; *P* = 0.001) and high MELD score (OR, 1.265 per point; 95% CI, 1.180‐1.356; *P* \< 0.001) were independent risk factors for postcolonoscopy renal failure.

The risk for GI bleeding not originating from polypectomy sites was also significantly elevated after colonoscopy (25 vs. 11; *P* = 0.023). MELD score (OR, 1.127 per point; 95% CI, 1.061‐1.197; *P* \< 0.001) was found to be an independent risk factor for postcolonoscopy GI bleeding.

Furthermore, there was a nonsignificant increase in bacterial infections (54 vs. 37 cases; *P* = 0.089), HE (47 vs. 32 cases; *P* = 0.109), pulmonary complications (10 vs. 3 cases; *P* = 0.058), and cardiac complications (7 vs. 4 cases; *P* = 0.391) in the postcolonoscopy and control time frames, respectively (Table [3](#hep30562-tbl-0003){ref-type="table"}).

Postpolypectomy hemorrhage occurred in 2 patients; both could be endoscopically managed. In 1 patient, colon perforation occurred after polypectomy, which was successfully treated conservatively.

Because the study duration was 13.5 years, the impact of the time of screening was measured on the detection of advanced adenomas and complication occurrence. There were no statistically significant differences regarding the time of screening on these outcome measures (Supporting Fig. [S1](#hep30562-sup-0001){ref-type="supplementary-material"}).

Clinical Course {#hep30562-sec-0015}
---------------

The median follow‐up time was 285 days (IQR, 106‐636). In this cohort, 260 patients (32.2%) died, 432 patients (53.3%) received a liver transplant, and 116 patients (14.4%) were waiting for a liver transplant at the end of the observation period. The 1‐year survival rate after liver transplantation was 91%, and the 2‐year survival rate was 88%.

Discussion {#hep30562-sec-0016}
==========

In this study, we assessed the diagnostic yield and safety of performing a screening colonoscopy in patients evaluated for liver transplantation. We found that CRC was diagnosed in 0.2% of the population and that advanced adenoma was diagnosed in 5.4%. Age was the only significant predictive factor for advanced neoplasia. Furthermore, colonoscopy with standard PEG bowel preparation was associated with a significantly increased risk for renal failure and nonpolypectomy GI bleeding, especially in patients with the most severe liver disease.

A key finding of the present study is the relatively low prevalence of CRC in this patient population. These results are consistent with those of comparable studies that did not find any case of CRC in patients undergoing pretransplantation evaluation.[6](#hep30562-bib-0006){ref-type="ref"}, [8](#hep30562-bib-0008){ref-type="ref"}, [39](#hep30562-bib-0039){ref-type="ref"} The 5.4% prevalence of advanced adenomas in our study was comparable to that reported by Weismuller et al. (prevalence, 5.8%; 243 patients with a mean age of 53 years) but differs markedly from the 13.9% prevalence (567 patients; median age of 54 years) reported by Jeschek et al.[6](#hep30562-bib-0006){ref-type="ref"}, [8](#hep30562-bib-0008){ref-type="ref"} These diverging results may be related to differences in study methodology, as the latter study results were not based on the actual diagnosed rate of advanced adenomas but were rather based on a statistical adjustment of this number, assuming the same rate of advanced adenomas among resected and nonresected polyps.[8](#hep30562-bib-0008){ref-type="ref"} The results of large cohort studies assessing the prevalence rate of advanced neoplasms in unselected healthy subjects, although of slightly older age, are in line with those in our study. Imperiale et al. reported a CRC rate of 0.6% and an advanced adenoma rate of 5.6% in 1,994 patients with a mean age of 60 years, and Stoop et al. found a rate of 0.5% and 8.2%, respectively, in 1,276 patients with a mean age of 61 years.[40](#hep30562-bib-0040){ref-type="ref"}, [41](#hep30562-bib-0041){ref-type="ref"}

Another important finding is that 53.5% of the population undergoing screening actually underwent liver transplantation. Although 14.4% are still waiting for a liver transplant, a substantial proportion of patients have died on the waiting list or were not placed on the waiting list because of contraindications for liver transplantation.[42](#hep30562-bib-0042){ref-type="ref"} Moreover, 9% of the 432 patients who underwent transplantation died within 1 year, and an additional 3% died in the second year after transplantation. Thus, the number of patients who could theoretically benefit from screening colonoscopy is further decreased by the operative and postoperative mortality.

Our results indicate that colonoscopy increases the risk for complications such as acute renal failure and GI bleeding. We hypothesize that this may be related to bowel preparation with an inherent substantial fluid load that may induce unwanted circulatory alterations and fluid shifts. Indeed, water retention in patients with a preexistent hyperdynamic circulation, increasing the portal venous pressure, has been reported in patients undergoing bowel preparation with decompensated liver disease, congestive heart failure, and chronic renal insufficiency.[13](#hep30562-bib-0013){ref-type="ref"}, [43](#hep30562-bib-0043){ref-type="ref"} Our study result that MELD score is the most important predictive factor for these complications after colonoscopy supports this theory.

The cecal intubation rate of 96.7% in our study is fairly similar to the rate of 83%‐96% found in other cohorts of patients evaluated for liver transplantation.[6](#hep30562-bib-0006){ref-type="ref"}, [39](#hep30562-bib-0039){ref-type="ref"} Multiple explanations are proposed for the slightly lower cecal intubation rate in this population compared with that in healthy subjects. The presence of ascites may lead to more mobile bowel loops floating in ascitic fluid and may lower the efficacy of external abdominal pressure to reduce loop formation.[39](#hep30562-bib-0039){ref-type="ref"} In addition, the cecal intubation rate may be adversely affected by other factors, including overall poor general condition and reduced possibilities for effective use of premedication.[39](#hep30562-bib-0039){ref-type="ref"} In the present study, MELD score was identified as an independent predictor for cecal intubation failure, which may support these hypotheses.

Currently, the American Association for the Study of the Liver clinical practice guideline recommends that liver transplantation candidates should undergo an age and risk factor--appropriate cancer screening, including colonoscopy without further specifications.[2](#hep30562-bib-0002){ref-type="ref"} The European Association for the Study of the Liver clinical practice guideline states that CRC screening is mandatory for candidates older than 50 years.[3](#hep30562-bib-0003){ref-type="ref"} However, in light of the currently available data, the indication for standard pre--liver transplantation screening colonoscopy may be questioned, considering the balance between yield and associated risks and costs and considering other important factors such as the substantial waiting list and perioperative mortality.

We suggest that other screening strategies should be considered. A possible alternative approach could be the use of a FIT as a general first‐line screening test in subjects aged 50 years or older and consideration of colonoscopy only in patients who have positive FIT results. Patients with IBD, primary sclerosing cholangitis, or other conditions associated with an increased risk for CRC should be managed according to generally accepted guidelines.

This study systematically assessed the complication risk of pre--liver transplantation screening colonoscopy, taking into account the underlying general risk for unwanted events associated with liver disease. The considerable size of the study population and the completeness of data are other factors likely contributing to the reliability of our results. A limitation is that patients who underwent colonoscopy in another center before referral were not taken into account. However, this was a relatively small group, and our study design reflects the real‐world situation in a referral hospital for liver transplantation. In addition, because of the retrospective design of the study, not all relevant factors, such as adequacy of bowel preparation, could be fully analyzed.

Future research projects regarding CRC screening in transplant candidates could focus on the assessment of factors relevant for more refined risk stratification in this population, such as age, sex, cause of liver disease, family history of CRC, body mass index, smoking and drinking habits, and comorbidities such as diabetes. It may be equally important to prospectively assess the results of alternative screening strategies.

In conclusion, this study describes the yield and safety of colonoscopy in patients evaluated for liver transplantation screening and provides arguments for why a reconsideration of guidelines regarding the necessity of colonoscopy in unselected patients seems appropriate. We propose that alternative colorectal screening strategies should be considered and further explored.
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